Description
An orally available HDAC inhibitor that selectively targets HDAC1 and 2 (IC50s = 0.15 and 0.29 µM, respectively), less potently inhibits HDAC3 and 11 (IC50s = 1.66 and 0.59 µM, respectively); induces hyperacetylation of histones, causes cell cycle blockade, and induces apoptosis in cancer cells in vitro
Formal name: N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]-benzamide
Synonyms: MGCD0103
Molecular weight: 396.4
CAS: 726169-73-9
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Small Molecule Inhibitors|Deacetylases||Research Area|Cancer|Cell Cycle||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Cardiovascular System|Cardiovascular Diseases|Heart Failure||Research Area|Cardiovascular System|Heart||Research Area|Epigenetics, Transcription, & Translation|Erasers|Histone Deacetylation